TY - JOUR
T1 - Association of lung fluorodeoxyglucose uptake with radiation pneumonitis after concurrent chemoradiation for non-small cell lung cancer
AU - Yue, Jinbo
AU - McKeever, Matthew
AU - Sio, Terence T.
AU - Xu, Ting
AU - Huo, Jinhai
AU - Shi, Qiuling
AU - Nguyen, Quynh Nhu
AU - Komaki, Ritsuko
AU - Gomez, Daniel R.
AU - Pan, Tinsu
AU - Wang, Xin Shelley
AU - Liao, Zhongxing
N1 - Publisher Copyright:
© 2017
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Background Increased uptake of fluorodeoxyglucose (FDG) by lung tissue could reflect inflammatory changes related to radiation pneumonitis (RP). In this secondary analysis of a clinical trial, we examined potential associations between posttreatment lung FDG uptake and RP severity in patients with non-small cell lung cancer (NSCLC) for up to 12 months after concurrent chemoradiation (CRT). Methods Subjects were 152 patients with NSCLC who had received concurrent CRT as part of the prospective trial NCT00915005. The following lung FDG variables were evaluated after CRT: maximum, mean, and peak standardized uptake values (SUVmax, SUVmean, SUVpeak) and global lung glycolysis (GLG; lung SUVmean × lung volume). RP severity was scored with the Common Terminology Criteria for Adverse Events v3.0. Results Significant associations were noted between PET findings and RP severity at 1–6 months (all P < 0.05), but not at 7–12 months after therapy (all P > 0.05). Lung FDG uptake at 1–3 months after treatment predicted later development of grade ≥2 RP (all P < 0.05), with cutoff values as follows: 4.54 for SUVmax, 3.69 for SUVpeak, 0.78 for SUVmean, and 2295 for GLG. Conclusions Lung FDG uptake correlated significantly with RP severity during the first 6 months after CRT. The cutoff values seem clinically meaningful for identifying patients at risk of developing RP after such therapy.
AB - Background Increased uptake of fluorodeoxyglucose (FDG) by lung tissue could reflect inflammatory changes related to radiation pneumonitis (RP). In this secondary analysis of a clinical trial, we examined potential associations between posttreatment lung FDG uptake and RP severity in patients with non-small cell lung cancer (NSCLC) for up to 12 months after concurrent chemoradiation (CRT). Methods Subjects were 152 patients with NSCLC who had received concurrent CRT as part of the prospective trial NCT00915005. The following lung FDG variables were evaluated after CRT: maximum, mean, and peak standardized uptake values (SUVmax, SUVmean, SUVpeak) and global lung glycolysis (GLG; lung SUVmean × lung volume). RP severity was scored with the Common Terminology Criteria for Adverse Events v3.0. Results Significant associations were noted between PET findings and RP severity at 1–6 months (all P < 0.05), but not at 7–12 months after therapy (all P > 0.05). Lung FDG uptake at 1–3 months after treatment predicted later development of grade ≥2 RP (all P < 0.05), with cutoff values as follows: 4.54 for SUVmax, 3.69 for SUVpeak, 0.78 for SUVmean, and 2295 for GLG. Conclusions Lung FDG uptake correlated significantly with RP severity during the first 6 months after CRT. The cutoff values seem clinically meaningful for identifying patients at risk of developing RP after such therapy.
KW - Clinician-rated toxicity
KW - FDG PET
KW - Non-small cell lung cancer
KW - Radiation pneumonitis
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85043253776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043253776&partnerID=8YFLogxK
U2 - 10.1016/j.ctro.2017.04.001
DO - 10.1016/j.ctro.2017.04.001
M3 - Article
C2 - 29594201
AN - SCOPUS:85043253776
SN - 2405-6308
VL - 4
SP - 1
EP - 7
JO - Clinical and Translational Radiation Oncology
JF - Clinical and Translational Radiation Oncology
ER -